9-Hydroxyellipticine (hydrochloride)

9-Hydroxyellipticine hydrochloride is a inhibitor of Topo II and RyR. 9-Hydroxyellipticine hydrochloride exhibits antitumor, antioxidant and catecholamine-releasing activities. 9-Hydroxyellipticine hydrochloride exhibits IC50 values of 1.6 μM and 1.2μM in Hela S-3 and 293T cells, respectively[1][2][3].

Product Specifications

CAS Number

[52238-35-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/9-hydroxyellipticine-hydrochloride.html

Purity

99.0

Solubility

H2O : 3 mg/mL (ultrasonic; warming)

Smiles

OC1=CC2=C(NC3=C2C(C)=C(C=NC=C4)C4=C3C)C=C1.[H]Cl

Molecular Formula

C17H15ClN2O

Molecular Weight

298.77

Precautions

H302, H315, H319, H335

References & Citations

[1]Renault G, et al. In vivo exposure to four ellipticine derivatives with topoisomerase inhibitory activity results in chromosome clumping and sister chromatid exchange in murine bone marrow cells. Toxicol Appl Pharmacol. 1987 Jun 30;89 (2) :281-6.|[2]Saeki K, et al. Cardioprotective effects of 9-hydroxyellipticine on ischemia and reperfusion in isolated rat heart. Jpn J Pharmacol. 2002 May;89 (1) :21-8.|[3]G Renault, et al. In vivo exposure to four ellipticine derivatives with topoisomerase inhibitory activity results in chromosome clumping and sister chromatid exchange in murine bone marrow cells. Toxicol Appl Pharmacol. 1987 Jun 30;89 (2) :281-6.|[4]Ohashi M, et al. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res. 1995 Sep;86 (9) :819-27.